According to Renovaro Biosciences's latest financial reports the company's current earnings are N/A. In 2023 the company made an earning of -โน3.55 Billion, an increase over its 2022 earnings that were of -โน9.35 Billion. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Year | Earnings | Change |
---|---|---|
2024 (TTM) | -โน12.52 Billion | 252.46% |
2023 | -โน3.55 Billion | -62.03% |
2022 | -โน9.35 Billion | 182.88% |
2021 | -โน3.31 Billion | 246.9% |
2020 | -โน0.96 Billion | 614.13% |
2019 | -โน0.14 Billion | -93.65% |
2018 | -โน2.11 Billion | 1119.78% |
2017 | -โน0.18 Billion | -29.21% |
2016 | -โน0.25 Billion | |
2014 | -โน0.23 Billion | 6701.79% |
2013 | -โน3.25 Million | 16.61% |
2012 | -โน2.79 Million |